Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
Show more...
FAQ
Cassava Sciences 今天的股价是多少?▼
SAVAW 当前价格为 $0.03 USD,过去 24 小时上涨了 +0%。在图表上更密切关注 Cassava Sciences 股价表现。
Cassava Sciences 的股票代码是什么?▼
根据交易所不同,股票代码可能会有所不同。例如,在 交易所,Cassava Sciences 的股票以代码 SAVAW 进行交易。
Cassava Sciences 去年的营收是多少?▼
Cassava Sciences 去年的营收为 0USD。
Cassava Sciences 去年的净利润是多少?▼
SAVAW 去年的净收益为 -118.14MUSD。
Cassava Sciences 会发放股息吗?▼
是的,SAVAW 的股息每 zh 发放一次。每股最新股息为 0 USD。截至今日,股息率(FWD)% 为 0%。
Cassava Sciences 有多少名员工?▼
截至四月 05, 2026,公司共有29名员工。
Cassava Sciences 属于哪个行业?▼
Cassava Sciences从事于Professional, Scientific, and Technical Services行业。
Cassava Sciences 何时完成拆股?▼
Cassava Sciences 最近没有进行任何拆股。
Cassava Sciences 的总部在哪里?▼
Cassava Sciences 的总部位于 US 的 Austin。